MSKCC and IMDC risk classification scores consist of clinical and laboratory parameters, which are able to classify patients prognosis. Baseline health related quality of life (HR-QoL) has been previously shown to have prognostic relevance in cancers. We therefore tested whether the addition of HR-QoL parameters to these tools can improve prognostic accuracy.
1100 1st line patients treated with sunitinib or pazopanib within the COMPARZ study (NCT00720941) were analyzed retrospectively. Baseline FACIT-Fatigue (F), FKSI-19 and the DRS-P subscale were used as continuous variable in prognostic factor analysis. Cox proportional hazards regression was performed to evaluate the potential prognostic ability of HR-QoL parameters on OS. Scores were adjusted for MSKCC and IMDC risk group scores separately.
Univariable analysis on prognosis, adjusted for risk groups.